Lakewood, CO, United States
Lakewood, CO, United States

Gambro is a global medical technology companythat manufactures products for Dialysis treatment.The company is a global leader in developing, manufacturing andsupplying products and therapies for Kidneyand Liver Dialysis, Myeloma Kidney Therapy, and otherextracorporeal therapies for Chronic and Acute patients.Gambro was founded in Lund, Sweden in 1964 by HolgerCrafoord and has approx. 8,000 employees, productionfacilities in 9 countries, and sales in more than100 countries. In September 2013, Baxter Intl. completed its acquisition of Gambro. Wikipedia.


Time filter

Source Type

The present disclosure relates to improved semipermeable membranes based on acrylonitrile copolymers for use in dialyzers for the extracorporeal treatment of blood in conjunction with hemodialysis, hemofiltration or hemodiafiltration. The present disclosure further relates to methods of producing such membranes.


An extracorporeal blood treatment apparatus (1) comprising a control unit (10) connectable to a blood warming device (200). The apparatus (1) comprises: an extracorporeal blood circuit (100) and at least one infusion line (15, 21, 25) connected to the extracorporeal blood circuit (100). A control unit (10) is configured to execute the following procedure: receiving a first value representative of a desired blood temperature (T_(des)) at an end (70) of a blood return line (7) configured to be connected to a venous vascular access of a patient (P); receiving at least a first signal relating to at least a flow rate (Q_(PBP), Q_(REP1), Q_(REP2)) of an infusion fluid in the at least one infusion line (15, 21, 25); calculating a set point value of an operating parameter (T_(OUT); P_(w)) to be imposed on the warming device (200) configured to heat a blood heating zone (H) of the extracorporeal blood circuit (100) in order to maintain the desired blood temperature (T_(des)) at the end (70) of the blood return line (7). The set point is calculated based on input parameters comprising: at least the first value representative of the desired blood temperature (T_(des)) and at least one selected in the group of: the first signal (Q_(REP1), Q_(PBP,) Q_(REP2)) and a second value representative of a temperature (T_(REP1), T_(PBP), T_(REP2)) of the at least one infusion fluid in the at least one infusion line (15, 21, 25).


Patent
Gambro | Date: 2017-04-26

A device for blood treatment by extracorporeal circulation including a filter having a first and a second chambers with a semi-permeable membrane, an arterial line connected to the first chamber and associated to a first pump Qb, a venous line out from the first chamber, a first pre-infusion line (109) connected to a citrate container and associated to a second pump Qpre1, a first post-infusion line connected to a calcium solution container associated to a third pump Qpost1, an effluent line at the outlet of the second chamber connected to a drain and associated to a fourth pump Qeff, a CPU including first means programmed to receive the signals output by at least one of the pumps and second means programmed to control third post-infusion pump Qpost1 (121) as a function of the flow rate Qb, Qeff, and Qpre1.


Patent
Gambro | Date: 2017-02-24

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising sodium chloride, at least one dry acid and at least one calcium salt, and optionally potassium salt, magnesium salt, and glucose. In an embodiment, the at least one calcium salt and the optional glucose are present as anhydrous components in the dialysis acid precursor composition.


Patent
Gambro | Date: 2017-03-07

A dialysis acid precursor assembly including: a bicarbonate containing concentrate and a dialysis acid concentrate solution including powder components mixed with water. The powder components include (1) a sodium chloride powder, (2) at least one dry acid powder, and (3) a magnesium chloride 4.5-hydrate (MgC1_(2).4.5H_(2)O) powder in a quantity such that a concentration of about 7.5-50 mM magnesium ions is provided in the dialysis acid concentrate solution.


A filter device (10) for filtration of fluids, in particular for the dialysis of blood. The filter device (10) comprises a housing (12) having a first end (14) and a second end (16) and defining a fluid chamber (18) extending between the first end (14) and the second end (16). The filter device (10) further comprises a first lid (20) provided at the first end (14) of the housing (12) and comprising a first fluid port (22), a first compartment (24), a second compartment (26) and a first internal separating wall (28) separating the first compartment (24) from the second compartment (26). The filter device (10) further comprises a second lid (30) provided at the second end (16) of the housing (12) and comprising a second fluid port (32), a third fluid port (33), a third compartment (34), a fourth compartment (36) and a second internal separating wall (38) separating the third compartment (34) from the fourth compartment (36). The filter device (10) further comprises a plurality of hollow fibers (40) arranged within the housing (12), wherein each of the plurality of hollow fibers (40) comprises a semi-permeable membrane and defines a fluid channel extending longitudinally through an interior of the respective hollow fiber (40). The filter device (10) further comprises a first sealing means (42) which separates the fluid chamber (18) from the first and the second compartment (24, 26), the first sealing means (42) having a first longitudinal end facing away from the second lid (30). The filter device (10) further comprises a second sealing means (46) which separates the fluid chamber (18) from the third and the fourth compartment (34, 36), the second sealing means (46) having a second longitudinal end facing away from the first lid (20). Still further, the filter device (10) comprises a fourth fluid port (50) and a fifth fluid port (52) both provided at the fluid chamber (18) and located between the first longitudinal end of the first sealing means (42) and the second longitudinal end of the second sealing means (46).


A5()A monitoring device is arranged to receive (401) at least one measurement signal obtained by at least one pressure sensor in an extracorporeal fluid system. The extracorporeal fluid system is in contact with a vascular system of a subject via a fluid connection. The monitoring device is configured to process (403) the measurement signal to identify pressure data that represents pulses originating from a first physiological phenomenon in the subject, excluding the heart of the subject. The extracorporeal fluid system may include an extracorporeal blood flow circuit, e.g. as part of a dialysis machine. The first physiological phenomenon may be any one of reflexes, voluntary muscle contractions, non-voluntary muscle contractions, a breathing system of the subject, an autonomous system of the subject for blood pressure regulation, or an autonomous system of the subject for body temperature regulation. The monitoring device may detect, present, track or predict (409) a disordered condition of the subj ect using the pressure data, or monitor (410) the integrity of the fluid connection based on the pressure data.


Patent
Gambro | Date: 2017-06-28

An adhesion strength detection system (10) includes: a die assembly (20) including a lower die (22), a fixture (30) fitted to the lower die (22), and a piston (40) insertable into the fixture (30), wherein a sample (100) may be fitted between the lower die (22) and the fixture (30), such that the piston (40) may come to rest on the sample (100); and a tensile testing machine (12) structured to accept the die assembly (20), the tensile testing machine (12) storing a force application program suitable for the sample (40), wherein the force application program when executed causes the piston (100) to be moved against the sample (100), the tensile testing machine (12) further configured to measure a resistive force applied by the sample (100) while the piston (40) is moved at least until delamination within the sample (100) occurs.


Patent
Gambro | Date: 2017-02-08

Extracorporeal blood treatment systems and methods to display information related to an alarm issued during extracorporeal blood treatments. For example, when an alarm is issued, an alarm region may be depicted on a graphical user interface. The alarm region may be configured to be docked into another region of the graphical user interface to, e.g., expose an operations region, etc.


Patent
Gambro | Date: 2017-03-29

A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 M, and rubidium in a concentration of 1.4-4.2 M. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper.

Loading Gambro collaborators
Loading Gambro collaborators